Ph I Study to Evaluate the Safety and Efficacy of Belinostat in Combination With Nivolumab Alone and With Ipilimumab in Patients With Previously Treated Metastatic or Advanced Carcinomas Enriched for ARID1A Loss of Function (Lof) Mutation

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Belinostat (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions
Acronyms BENEFIT

Most Recent Events

26 Oct 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
15 Oct 2020 Planned initiation date changed from 1 Sep 2020 to 1 Oct 2020.
20 Mar 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight